Edition:
United States

Spectrum Pharmaceuticals Inc (SPPI.OQ)

SPPI.OQ on NASDAQ Stock Exchange Global Select Market

19.12USD
3:59pm EST
Change (% chg)

$-0.38 (-1.95%)
Prev Close
$19.50
Open
$19.51
Day's High
$19.60
Day's Low
$18.83
Volume
311,651
Avg. Vol
403,902
52-wk High
$21.95
52-wk Low
$3.85

Latest Key Developments (Source: Significant Developments)

Spectrum Pharmaceuticals reports Q3 non-GAAP loss per share of $0.11
Thursday, 2 Nov 2017 04:02pm EDT 

Nov 2 (Reuters) - Spectrum Pharmaceuticals Inc :Spectrum Pharmaceuticals reports third quarter 2017 financial results and pipeline update.Q3 non-GAAP loss per share $0.11.Q3 loss per share $0.22.Q3 revenue $36.4 million.  Full Article

Spectrum Pharmaceuticals announces initiation of a multicenter phase 2 trial of poziotinib in non-small cell lung cancer patients with Exon 20 insertion mutation in EGFR or HER2
Monday, 30 Oct 2017 07:00am EDT 

Oct 30 (Reuters) - Spectrum Pharmaceuticals Inc :Spectrum Pharmaceuticals announces initiation of a multicenter phase 2 trial of poziotinib in non-small cell lung cancer (NSCLC) patients with Exon 20 insertion mutation in EGFR or HER2.  Full Article

Spectrum Pharmaceuticals provides update on at-the-market facility
Friday, 29 Sep 2017 07:00am EDT 

Sept 29 (Reuters) - Spectrum Pharmaceuticals Inc :Spectrum Pharmaceuticals Inc provides update on at-the-market facility.Spectrum Pharmaceuticals Inc - ‍expects to use proceeds from financing to continue develop its pipeline, provide more flexibility to its capital structure​.Spectrum Pharmaceuticals Inc - ‍between August 11 and September 29 offering program resulted in aggregate net proceeds of about $90.2 million.​.  Full Article

Spectrum Pharma starts phase 3 qapzola trial
Monday, 14 Aug 2017 07:00am EDT 

Aug 14 (Reuters) - Spectrum Pharmaceuticals Inc :Spectrum pharmaceuticals announces initiation of the registrational phase 3 trial of qapzola™ (apaziquone) in patients with non-muscle invasive bladder cancer (nmibc).Says ‍expect to file a registration application (bla) with fda for rolontis in 2018​.  Full Article

Spectrum Pharma enters into an at market issuance sales agreement
Friday, 4 Aug 2017 05:42pm EDT 

Aug 4 (Reuters) - Spectrum Pharmaceuticals Inc -:Spectrum Pharmaceuticals Inc - on August 4, 2017, co entered into an at market issuance sales agreement - sec filing.Spectrum Pharmaceuticals Inc - co may offer and sell up to an aggregate of $150 million of shares of company's common stock, par value $0.001 per share.  Full Article

Spectrum Pharmaceuticals Q2 loss per share $0.26
Thursday, 3 Aug 2017 04:02pm EDT 

Aug 3 (Reuters) - Spectrum Pharmaceuticals Inc :Spectrum Pharmaceuticals reports second quarter 2017 financial results and pipeline update.Q2 non-GAAP loss per share $0.11.Q2 loss per share $0.26.Q2 revenue $34.3 million.  Full Article

Spectrum Pharmaceuticals reports Q1 loss per share $0.29
Tuesday, 2 May 2017 04:02pm EDT 

May 2 (Reuters) - Spectrum Pharmaceuticals Inc :Spectrum Pharmaceuticals reports first quarter 2017 financial results and pipeline update.Q1 non-gaap loss per share $0.14.Q1 loss per share $0.29.Q1 revenue $29.1 million versus i/b/e/s view $32.2 million.Q1 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S.Spectrum Pharmaceuticals Inc - company ended quarter with cash and cash equivalents of $137 million..  Full Article

Spectrum Pharmaceuticals announces initiation of a phase 2 trial of Poziotinib
Thursday, 30 Mar 2017 07:00am EDT 

Spectrum Pharmaceuticals Inc : Spectrum Pharmaceuticals announces initiation of a phase 2 trial of Poziotinib in non-small cell lung cancer patients with EGFR exon 20 insertion mutations .Top-Line results are expected before year-end.  Full Article

Spectrum Pharmaceuticals reports Q4 loss per share of $0.22
Wednesday, 8 Mar 2017 04:02pm EST 

Spectrum Pharmaceuticals Inc : Spectrum Pharmaceuticals reports fourth quarter 2016 and full year 2016 financial results and pipeline update . Q4 non-GAAP loss per share $0.10 . Q4 loss per share $0.22 . Q4 revenue $35.2 million versus I/B/E/S view $31.1 million . Q4 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S .Says Rolontis(eflapegrastim) pivotal program is on track for spectrum to file BLA next year.  Full Article

Spectrum Pharma receives complete response letter from FDA for Qapzola
Friday, 18 Nov 2016 06:37am EST 

Spectrum Pharmaceuticals Inc : Spectrum Pharmaceuticals Inc says on November 15, 2016, company met with FDA to discuss strategy for further development of Qapzola . Spectrum Pharmaceuticals - Based on discussions with FDA, co evaluating new smaller study that would replace ongoing phase 3 program . Spectrum Pharmaceuticals -On November 17 received complete response letter from FDA with respect to NDA for Qapzola Source: (http://bit.ly/2g1VIog) Further company coverage: [SPPI.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

BRIEF-Spectrum Pharmaceuticals reports Q3 non-GAAP loss per share of $0.11

* Spectrum Pharmaceuticals reports third quarter 2017 financial results and pipeline update